84.32
-3.555(-4.05%)
Currency In USD
| Previous Close | 87.87 |
| Open | 86.38 |
| Day High | 86.64 |
| Day Low | 82.89 |
| 52-Week High | 122.2 |
| 52-Week Low | 60.7 |
| Volume | 369,203.81 |
| Average Volume | 828,255 |
| Market Cap | 5.78B |
| PE | -26.94 |
| EPS | -3.13 |
| Moving Average 50 Days | 87.24 |
| Moving Average 200 Days | 98.55 |
| Change | -3.56 |
Rhythm Pharmaceuticals Announces Additional Positive Data from Phase 3 TRANSCEND trial of Setmelanotide in Patients with Acquired Hypothalamic Obesity
GlobeNewswire Inc.
Mar 01, 2026 5:30 PM GMT
-- -18.8% placebo-adjusted difference in BMI reduction achieved in all patients (N=142) at 52 weeks, including 12 Japanese patients and 10 supplemental patients with acquired hypothalamic obesity -- -- March 20, 2026 PDUFA goal date for sNDA for set
Rhythm Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, February 26, 2026
GlobeNewswire Inc.
Feb 17, 2026 1:00 PM GMT
BOSTON, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced that
Rhythm Pharmaceuticals Announces Participation in Upcoming Guggenheim Biotech Summit
GlobeNewswire Inc.
Feb 05, 2026 1:00 PM GMT
BOSTON, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced that